References
- Weyer K, Mirzayev F, Migliori GB et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert MTB /RIF. Eur. Resp. J. 42(1), 252–271 (2013).
- Helb D, Jones M, Story E et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48(1), 229–237 (2010).
- Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363(11), 1005–1015 (2010).
- Steingart K, Sohn H, Schiller I et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. (1), CD009593 (2013).
- Girosi F, Olmsted SS, Keeler E et al. Developing and interpreting models to improve diagnostics in developing countries. Nature 444( Suppl. 444), 3–8 (2006).
- Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 9(9), e1001306 (2012).
- Trebucq A, Enarson DA, Chiang CY et al. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int. J. Tuberc. Lung Dis. 15(12), 1567–1572 (2011).
- Schnippel K, Meyer-Rath G, Long L et al. Scaling up Xpert MTB /RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop. Med. Int. Health 17(9), 1142–1151 (2012).
- Sun A, Pai M, Salje H, Satyanarayana S, Deo S, Dowdy D. Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia. Am. J. Epidemiol. doi:10.1093/aje/kwt210 (2013) (Epub ahead of print).
- Niemz A, Boyle DS. Nucleic acid testing for TB at the point-of-care in high burden countries. Expert Rev. Mol. Diagn. 12(7), 687–701 (2012).
- UNITAID. Tuberculosis: Diagnostic Technology and Market Landscape (2nd Edition). World Health Organization, Geneva, Switzerland (2013).
- Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur. Resp. J. 42(2), 544–547 (2013).
- Denkinger CM, Grenier J, Stratis AK, Akkihal A, Pant-Pai N, Pai M. Mobile health to improve tuberculosis care and control: a call worth making. Int. J. Tuberc. Lung Dis. 17(6), 719–727 (2013).
- Pai M. Diagnostics for tuberculosis: what test developers want to know. Expert Rev. Mol. Diagn. 13(4), 1–4 (2013).
- Pai M. Tuberculosis diagnostics: test developers’ FAQs. Int. J. Tuberc. Lung Dis. 17(5), 570–571 (2013).
Websites
- WHO monitoring of Xpert MTB/RIF roll-out. www.who.int/tb/laboratory/mtbrifrollout/en/index.html
- Foundation for Innovative New Diagnostics. Negotiated prices for Xpert® MTB/RIF. www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/xpert_mtb_rif.html
- Tuberculosis Control – India, Ministry of Health and Family Welfare. www.tbcindia.nic.in/
- TB diagnostics: top 10 FAQs by test developers. www.tbfaqs.org/